Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Ketorolac Effects on Post-operative Pain and Lumbar Fusion

A double blind prospective randomized trial of IV ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.

Participants needed: 140
Trial details
Phase: Phase 4Age: 18-85Biological sex: AllType: InterventionalSponsor: University of Maryland St. Joseph Medical CenterUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

18-85 years old (inclusive) [+4]

< 18 or > 85 years old [+8]

Read more
Status: Recruiting

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of Maryland St. Joseph Medical CenterUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB [+4]

Bleeding as primary etiology of hypotension, as determined by > 4 units RBC tran... [+4]

Read more
Status: Not yet recruiting

Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy

Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord will be a safe and effective treatment for CIPN, reducing pain in the lower extremities by at least 50%.

Participants needed: 10
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of Maryland St. Joseph Medical CenterUpdated: Sep 19, 2024
Eligibility criteria

CIPN as diagnosed by Oncology and/or neurology [+5]

Platelet count less than 100k/mm3 [+4]

Read more